1. In Vivo
  2. >>Market Intelligence

Device/Diagnostics Quarterly Deal Statistics, Q3 2016

A look at financing, M&A and alliance activity July–September 2016

 
• By Amanda Micklus and Maureen Riordan

Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.

IV1610_Calendar_1200X675

Financing by device companies during the third quarter of 2016 totaled $3 billion, doubling Q2's $1.5 billion. As in the past two quarters, debt offerings continue to make up the highest percentage of the financing dollars at 72% in Q3. (See Exhibit 1.) Most of the $2.2 billion in Q3 debt dollars are attributed to the outlier $1.75 billion sale of 9.625% second lien senior secured notes due 2021 by Acelity LP Inc.’s wound care and regenerative medicine subsidiaries Kinetic Concepts Inc. and KCI USA Inc. [See Deal]; this single transaction accounted for 57% of Q3’s total dollar volume and is also the largest-know debt raise by a medtech company since Strategic Transactions started tracking this activity in 1991. Acelity says the proceeds will repay existing debt. (The company also offered $400 million principal amount of first lien senior secure notes in February 2016 [See Deal].)

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

Financing Quarterly Statistics, Q2 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

More from In Vivo

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

Q&A: Commercializing Oncology Products, Strategic Insights For Drug Developers

 
• By Jo Shorthouse

John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.